Kinetics of [methyl-<sup>11</sup>C]Thymidine in Patients with Squamous Cell Carcinoma of the Head and Neck

Eijkeren, Marc E. Van; Thierens, Hubert; Seuntjens, J; Goethals, Patrick; Lemahieu, Ignace; Strijckmans, Karel

doi:10.3109/02841869609084008

Cited by 21 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early clinical studies with TdR-PET demonstrated feasibility in a variety of tumors, including non-Hodgkin's lymphomas [70], head and neck tumors [71,72], lung cancers [73], sarcomas [73], gastrointestinal cancers [74] and a variety of intraabdominal malignancies [75]. In general, images were of lower contrast than FDG PET, due to image background from labeled TdR metabolites [76,77].…”

Section: C-thymidine and Thymidine Analoguesmentioning

confidence: 98%

Positron emission tomography imaging as a cancer biomarker

Mankoff

2007

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

The practice of oncology is changing, with novel biologic agents broadening our therapeutic armamentarium. Along with excitement and promise, multiple new challenges arise. The concept of 'individualized cancer care,' where therapies are selected based on the unique characteristics of a patient's tumor, is gaining favor as an approach to address the heterogeneity of cancer. As a result, we must strive to discover biomarkers with prognostic and predictive value to improve drug selection, alteration and development. Metabolic and molecular imaging with PET appears at the forefront of this critical field. In this review, we discuss cancer biomarker development, opportunities for PET to elucidate tumor biology and the potential role of PET in clinical research and practice.

show abstract

Section: C-thymidine and Thymidine Analoguesmentioning

confidence: 98%

Positron emission tomography imaging as a cancer biomarker

Mankoff

2007

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…11 C-thymidine allows one to image this pathway, with utility of this approach demonstrated in small cell lung cancer, sarcomas, head and neck cancer, and gliomas. [6][7][8] However, its use in clinical applications is complicated by its metabolism, leading to reduced specificity of uptake as a measure of proliferation when evaluating static PET images. Therefore, 18 F-FLTwas developed to overcome these limitations, demonstrating excellent imaging properties (Fig.…”

Section: Imaging Tumor Proliferationmentioning

confidence: 99%

“…Thymidine is also taken up from the bloodstream, and after action by thymidine kinase 1, the resulting thymidine monophosphate can be incorporated into DNA. 11 C-thymidine allows one to image this pathway, with utility of this approach demonstrated in small cell lung cancer, sarcomas, head and neck cancer, and gliomas 6–8 . However, its use in clinical applications is complicated by its metabolism, leading to reduced specificity of uptake as a measure of proliferation when evaluating static PET images.…”

Section: Imaging Tumor Proliferationmentioning

confidence: 99%

Positron Emission Tomography Imaging of Tumor Proliferation and DNA Repair

Shields,

Chen

2024

Cancer J

View full text Add to dashboard Cite

Positron emission tomography (PET) is an established tool for molecular imaging of cancers, and its role in diagnosis, staging, and phenotyping continues to evolve and expand rapidly. PET imaging of increased glucose utilization with 18F-fluorodeoxyglucose is now entrenched in clinical oncology practice for improving prognostication and treatment response assessment. Additional critical processes for cancer cell survival can also be imaged by PET, helping to inform individualized treatment selections for patients by improving our understanding of cell survival mechanisms and identifying relevant active mechanisms in each patient. The critical importance of quantifying cell proliferation and DNA repair pathways for prognosis and treatment selection is highlighted by the nearly ubiquitous use of the Ki-67 index, an established histological quantitative measure of cell proliferation, and BRCA mutation testing for treatment selection. This review focuses on PET advances in imaging and quantifying cell proliferation and poly(ADP-ribose)polymerase expression that can be used to complement cancer phenotyping approaches that will identify the most effective treatments for each individual patient.

show abstract

“…Numerous PET studies using [ methyl - 11 C]thymidine, ,,,,− and [ 2 - 11 C]thymidine, ,,− have been performed to evaluate cell proliferation in human tissue tumors, including lymphoma, head and neck tumors, brain tumors, renal cell carcinoma, lung cancer, and gastrointestinal cancers.…”

Section: Nucleotides Nucleosides and Nucleobasesmentioning

confidence: 99%

Radiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds

et al. 2022

View full text Add to dashboard Cite

The presence of positron emission tomography (PET) centers at most major hospitals worldwide, along with the improvement of PET scanner sensitivity and the introduction of total body PET systems, has increased the interest in the PET tracer development using the short-lived radionuclides carbon-11. In the last few decades, methodological improvements and fully automated modules have allowed the development of carbon-11 tracers for clinical use. Radiolabeling natural compounds with carbon-11 by substituting one of the backbone carbons with the radionuclide has provided important information on the biochemistry of the authentic compounds and increased the understanding of their in vivo behavior in healthy and diseased states. The number of endogenous and natural compounds essential for human life is staggering, ranging from simple alcohols to vitamins and peptides. This review collates all the carbon-11 radiolabeled endogenous and natural exogenous compounds synthesised to date, including essential information on their radiochemistry methodologies and preclinical and clinical studies in healthy subjects.

show abstract

Kinetics of [methyl-¹¹C]Thymidine in Patients with Squamous Cell Carcinoma of the Head and Neck

Cited by 21 publications

References 13 publications

Positron emission tomography imaging as a cancer biomarker

Positron emission tomography imaging as a cancer biomarker

Positron Emission Tomography Imaging of Tumor Proliferation and DNA Repair

Radiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds

Contact Info

Product

Resources

About

Kinetics of [methyl-11C]Thymidine in Patients with Squamous Cell Carcinoma of the Head and Neck

Cited by 21 publications

References 13 publications

Positron emission tomography imaging as a cancer biomarker

Positron emission tomography imaging as a cancer biomarker

Positron Emission Tomography Imaging of Tumor Proliferation and DNA Repair

Radiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds

Contact Info

Product

Resources

About

Kinetics of [methyl-¹¹C]Thymidine in Patients with Squamous Cell Carcinoma of the Head and Neck